<DOC>
	<DOCNO>NCT00003974</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's tumor may help body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy treat patient undergone surgery remove stage I , stage II , stage IIIA non-small cell lung cancer stage I stage II mesothelioma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage I , Stage II , Stage IIIA Non-small Cell Lung Cancer With Stage I Stage II Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : I . Define immunological parameter cytolytic T cell T helper cell activity associate skin test vaccination autologous lung tumor associate antigen detoxPC patient curatively resect stage I , II , IIIA non-small cell lung cancer ( NSCLC ) stage I II mesothelioma . II . Evaluate response associate enhanced antitumor immune status patient population treatment regimen . OUTLINE : Patients undergo delay type hypersensitivity skin test autologous tumor associate antigen ( TAA ) memory antigen ( i.e. , Monilia , PPD , Trichophyton ) intradermally 1-4 week follow surgical tumor resection . At week 4-9 , patient receive low dose cyclophosphamide IV . At 3 day follow chemotherapy , patient receive autologous TAA DetoxPC intradermally 3 dos 4 week . At 2-3 week follow vaccination , patient undergo repeat skin testing . At week 6-12 , patient positive skin test undergo biopsy skin test/vaccination site follow leukapheresis week 12-20 T cell exhibit active antitumor reactivity . Patients stable regressive disease receive additional vaccination course week 20 thereafter . Patients follow 5 year . PROJECTED ACCRUAL : A total 20 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove primary stage I ( T2 , N0 ) , II , IIIA nonsmall cell lung cancer ( NSCLC ) curatively resect pneumonectomy , lobectomy , wedge resection OR Stage I II mesothelioma Measurable disease Lesions must least 3 cm diameter PATIENT CHARACTERISTICS : Age : 20 70 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No malignancy except nonmelanoma skin cancer No history severe allergies No history autoimmune disease Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No concurrent glucocorticoid Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent nonsteroidal antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>